Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.

Adolescent Adult Aged Animals Candida albicans / immunology Candidiasis, Chronic Mucocutaneous / genetics Disease Models, Animal Female Humans Immunity, Mucosal / genetics Immunologic Surveillance / genetics Interferon-gamma / genetics Interleukins / genetics Janus Kinases / genetics Male Mice Mice, Inbred BALB C Middle Aged Mouth Mucosa / immunology Polyendocrinopathies, Autoimmune / genetics Receptors, Interleukin-17 / genetics STAT1 Transcription Factor / genetics T-Lymphocytes / immunology Young Adult Interleukin-22

Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 02 07 2019
revised: 05 07 2020
accepted: 13 11 2020
entrez: 15 1 2021
pubmed: 16 1 2021
medline: 10 2 2021
Statut: ppublish

Résumé

Human monogenic disorders have revealed the critical contribution of type 17 responses in mucosal fungal surveillance. We unexpectedly found that in certain settings, enhanced type 1 immunity rather than defective type 17 responses can promote mucosal fungal infection susceptibility. Notably, in mice and humans with

Identifiants

DOI: 10.1126/science.aay5731 PMID: 33446526 PMC: PMC8326743
pubmed: 33446526
pii: 371/6526/eaay5731
doi: 10.1126/science.aay5731
pmc: PMC8326743
mid: NIHMS1666504
pii:
doi:

Substances chimiques

Interleukins 0
Receptors, Interleukin-17 0
STAT1 Transcription Factor 0
Interferon-gamma 82115-62-6
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDCR NIH HHS
ID : R01 DE026600
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124566
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI110820
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIC DC000086
Pays : United States
Organisme : NIDCR NIH HHS
ID : R00 DE026856
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK095735
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI001175
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI141622
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA034196
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
J Antimicrob Chemother. 2018 Aug 1;73(8):2089-2094
pubmed: 29788070
J Immunol. 2009 Mar 15;182(6):3902-18
pubmed: 19265170
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
FEMS Microbiol Ecol. 2003 Feb 1;43(1):1-11
pubmed: 19719691
Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):E8277-E8285
pubmed: 27930337
J Allergy Clin Immunol. 2019 Apr;143(4):1626-1629.e5
pubmed: 30576757
Immunity. 2020 Sep 15;53(3):672-684.e11
pubmed: 32750333
Lancet Infect Dis. 2015 Aug;15(8):968-80
pubmed: 26049967
J Exp Med. 2009 Feb 16;206(2):299-311
pubmed: 19204111
J Clin Immunol. 2020 Aug;40(6):807-819
pubmed: 32572726
J Clin Invest. 2006 May;116(5):1292-301
pubmed: 16628255
J Immunol. 2003 Dec 1;171(11):6164-72
pubmed: 14634132
J Clin Invest. 2018 Aug 1;128(8):3595-3604
pubmed: 30035749
J Allergy Clin Immunol. 2017 Jun;139(6):2016-2020.e5
pubmed: 28111307
J Clin Invest. 2010 May;120(5):1762-73
pubmed: 20364087
JCI Insight. 2016 Aug 18;1(13):
pubmed: 27588307
Nat Immunol. 2011 Mar;12(3):255-63
pubmed: 21278737
Infect Immun. 2015 Mar;83(3):958-65
pubmed: 25547797
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
Virol J. 2014 Apr 18;11:71
pubmed: 24742045
J Virol Methods. 2003 Sep;112(1-2):107-13
pubmed: 12951218
J Autoimmun. 2020 Jul;111:102436
pubmed: 32220507
J Exp Med. 2010 Feb 15;207(2):291-7
pubmed: 20123958
J Immunol. 2008 Sep 15;181(6):4072-9
pubmed: 18768863
J Exp Med. 2011 Aug 1;208(8):1635-48
pubmed: 21727188
J Antimicrob Chemother. 2018 Jan 1;73(1):151-155
pubmed: 29040636
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503875
J Allergy Clin Immunol. 2012 Jul;130(1):145-54.e9
pubmed: 22677045
J Immunol Methods. 2013 Aug 30;394(1-2):49-54
pubmed: 23672778
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13009-14
pubmed: 18755889
Cell Host Microbe. 2016 Nov 9;20(5):606-617
pubmed: 27923704
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Allergy Clin Immunol. 2015 Feb;135(2):551-3
pubmed: 25662309
PLoS Pathog. 2018 May 21;14(5):e1007069
pubmed: 29782555
J Clin Invest. 2020 Jun 1;130(6):3158-3171
pubmed: 32163377
Immunol Rev. 2019 Jan;287(1):103-120
pubmed: 30565240
J Exp Med. 2015 May 4;212(5):619-31
pubmed: 25918342
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Gigascience. 2013 Nov 26;2(1):16
pubmed: 24280061
J Immunol. 2014 Feb 15;192(4):1745-52
pubmed: 24442441
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Annu Rev Immunol. 2018 Apr 26;36:157-191
pubmed: 29237128
Drugs. 2019 Jan;79(1):99-103
pubmed: 30623346
J Allergy Clin Immunol. 2019 Sep;144(3):750-763
pubmed: 31129129
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Science. 2020 Aug 7;369(6504):706-712
pubmed: 32527925
J Virol. 2011 Oct;85(19):10346-53
pubmed: 21813614
mBio. 2017 Mar 21;8(2):
pubmed: 28325761
J Vis Exp. 2016 Feb 16;(108):53736
pubmed: 26967370
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18193-8
pubmed: 17991771
N Engl J Med. 2011 Jul 7;365(1):54-61
pubmed: 21714643
PLoS Pathog. 2015 Oct 02;11(10):e1005164
pubmed: 26431538
Oral Microbiol Immunol. 2006 Aug;21(4):252-5
pubmed: 16842510
J Leukoc Biol. 2016 Jun;99(6):1153-64
pubmed: 26729813
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Sci Transl Med. 2018 Oct 17;10(463):
pubmed: 30333238
Curr Protoc Immunol. 2001 May;Chapter 4:Unit 4.1
pubmed: 18432792
Annu Rev Immunol. 2015;33:823-74
pubmed: 25706096
J Clin Immunol. 2012 Apr;32(2):238-45
pubmed: 22170314
Immunity. 2010 Mar 26;32(3):392-402
pubmed: 20303298
Curr Protoc Immunol. 2017 Nov 1;119:19.15.1-19.15.25
pubmed: 29091261
Annu Rev Immunol. 2019 Apr 26;37:247-267
pubmed: 30633609
Science. 2002 Nov 15;298(5597):1395-401
pubmed: 12376594
Science. 2011 Apr 1;332(6025):65-8
pubmed: 21350122
Immunity. 2013 Oct 17;39(4):676-86
pubmed: 24120361
Nat Microbiol. 2018 Jan;3(1):53-61
pubmed: 29133884
Mucosal Immunol. 2015 Mar;8(2):221-31
pubmed: 25005360
J Exp Med. 2005 Sep 19;202(6):805-15
pubmed: 16172259
Nat Protoc. 2012 Mar 08;7(4):637-42
pubmed: 22402633
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
J Dent Res. 2020 Jun;99(6):676-684
pubmed: 32109361
J Exp Med. 2010 Feb 15;207(2):299-308
pubmed: 20123959

Auteurs

Timothy J Break (TJ)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0001-5987-7817

Vasileios Oikonomou (V)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0002-7553-0159

Nicolas Dutzan (N)

Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.
ORCID: 0000-0001-8343-0214

Jigar V Desai (JV)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0002-8823-0796

Marc Swidergall (M)

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
ORCID: 0000-0002-5261-6267

Tilo Freiwald (T)

Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.
ORCID: 0000-0002-4759-717X

Daniel Chauss (D)

Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.

Oliver J Harrison (OJ)

Metaorganism Immunity Section, Laboratory of Immune System Biology, NIAID, Bethesda, MD, USA.
ORCID: 0000-0003-1515-9586

Julie Alejo (J)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.

Drake W Williams (DW)

Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.
ORCID: 0000-0002-7718-2098

Stefania Pittaluga (S)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.
ORCID: 0000-0001-7688-1439

Chyi-Chia R Lee (CR)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.
ORCID: 0000-0002-5306-7781

Nicolas Bouladoux (N)

Metaorganism Immunity Section, Laboratory of Immune System Biology, NIAID, Bethesda, MD, USA.
ORCID: 0000-0003-1593-671X

Muthulekha Swamydas (M)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0002-8665-7016

Kevin W Hoffman (KW)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0003-4284-4108

Teresa Greenwell-Wild (T)

Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.

Vincent M Bruno (VM)

Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
ORCID: 0000-0003-1683-2015

Lindsey B Rosen (LB)

Immunopathogenesis Section, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0001-5894-3878

Wint Lwin (W)

Diabetes Center, University of California, San Francisco, CA, USA.

Andy Renteria (A)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0002-6978-1349

Sergio M Pontejo (SM)

Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, MD, USA.
ORCID: 0000-0002-7756-9831

John P Shannon (JP)

Viral Immunity and Pathogenesis Unit, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0002-8722-2209

Ian A Myles (IA)

Epithelial Therapeutics Unit, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0001-9316-3703

Peter Olbrich (P)

Immunopathogenesis Section, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0001-9853-7903

Elise M N Ferré (EMN)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
ORCID: 0000-0002-3285-7768

Monica Schmitt (M)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.

Daniel Martin (D)

Genomics and Computational Biology Core, NIDCR, Bethesda, MD, USA.
ORCID: 0000-0002-8880-9087

Daniel L Barber (DL)

T Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, Bethesda, MD, USA.
ORCID: 0000-0003-0344-9447

Norma V Solis (NV)

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.

Luigi D Notarangelo (LD)

Immune Deficiency Genetics Section, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0002-8335-0262

David V Serreze (DV)

Jackson Laboratory, Bar Harbor, ME, USA.
ORCID: 0000-0001-7614-5925

Mitsuru Matsumoto (M)

Division of Molecular Immunology, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.

Heather D Hickman (HD)

Viral Immunity and Pathogenesis Unit, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0003-4168-4894

Philip M Murphy (PM)

Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, MD, USA.
ORCID: 0000-0002-1080-8201

Mark S Anderson (MS)

Diabetes Center, University of California, San Francisco, CA, USA.
ORCID: 0000-0002-3093-4758

Jean K Lim (JK)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0002-4572-6417

Steven M Holland (SM)

Immunopathogenesis Section, LCIM, NIAID, Bethesda, MD, USA.
ORCID: 0000-0003-3207-5464

Scott G Filler (SG)

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
ORCID: 0000-0001-7278-3700

Behdad Afzali (B)

Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.
ORCID: 0000-0003-2968-1156

Yasmine Belkaid (Y)

Metaorganism Immunity Section, Laboratory of Immune System Biology, NIAID, Bethesda, MD, USA.
ORCID: 0000-0001-9962-3571

Niki M Moutsopoulos (NM)

Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.
ORCID: 0000-0002-7365-6735

Michail S Lionakis (MS)

Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. lionakism@mail.nih.gov.
ORCID: 0000-0003-4994-9500

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Eucaryotes › Animaux › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Eucaryotes › Champignons › Levures › Candida › Candida albicans › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Candidose mucocutanée chronique › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité muqueuse › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Phénomènes du système immunitaire › Surveillance immunologique › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Janus kinases › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Système stomatognathique › Bouche › Muqueuse de la bouche › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Polyendocrinopathies auto-immunes › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux interleukines › Récepteurs à l'interleukine-17 › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription STAT › Facteur de transcription STAT-1 › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Aberrant type 1 immunity drives susceptibility...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Aberrant type 1 immunity drives susceptibility...